Skip to main content
Clinical Trials/ACTRN12611000432910
ACTRN12611000432910
Not yet recruiting
未知

A Pilot Clinical Study to Evaluate the Potential of AMLAMAX (trademark (TM)) (Emblica Officinalis) Extract on Raising HDL-Cholesterol levels and Decreasing Plasma Amyloid beta Levels in subjective memory complainers with low HDL-C.

Prof Ralph Martins0 sites167 target enrollmentApril 27, 2011

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Prof Ralph Martins
Enrollment
167
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 27, 2011
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Prof Ralph Martins

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria: The eligibility criteria will be as follows: 1\) age 35\-65 years, 2\) HDL\-C levels \<1\.03 mMol/L in men or \<1\.29 mMol/L in women 3\) triglyceride (TG) levels \>1\.7 mMol/L.
  • psychometric testing using standardized, validated diagnostic tools.
  • Mini\-Mental State Examination (MMSE) score greater than or equal to 24\.
  • 2\. The classification of SMC will be obtained from a single question, yes/no response from the CAMDEX\-R (Do you have any difficulty with your memory?
  • 2\.A score greater than or equal to 80\-81 (CAMCOG)\-R (cognitive component of the CAMDEX\-R).
  • 4\. a score of below, equal and above age and education norms on the California Verbal Learning Test (CVLT).

Exclusion Criteria

  • Patients suffering from heart failure, chronic liver disease, eGFR\<60 ml/min.

Outcomes

Primary Outcomes

Not specified

Similar Trials